Humacyte (NASDAQ:HUMA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note published on Wednesday,Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Several other equities analysts have also recently issued reports on the stock. Benchmark restated a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Humacyte has a consensus rating of “Buy” and an average price target of $13.71.

Humacyte Price Performance

HUMA stock opened at $2.99 on Wednesday. The company has a 50 day simple moving average of $4.05 and a 200 day simple moving average of $4.76. The stock has a market cap of $376.32 million, a price-to-earnings ratio of -2.23 and a beta of 1.36. Humacyte has a 1 year low of $2.81 and a 1 year high of $9.97.

Institutional Investors Weigh In On Humacyte

A number of institutional investors have recently modified their holdings of HUMA. Vontobel Holding Ltd. bought a new stake in shares of Humacyte in the 4th quarter valued at $50,000. Petros Family Wealth LLC bought a new stake in shares of Humacyte in the 4th quarter valued at $50,000. Syon Capital LLC bought a new stake in shares of Humacyte in the 4th quarter valued at $54,000. Brookstone Capital Management bought a new stake in shares of Humacyte in the 4th quarter valued at $56,000. Finally, ACT Wealth Management LLC bought a new stake in shares of Humacyte in the 4th quarter valued at $57,000. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.